Idiopathic pulmonary fibrosis in the era of antifibrotic therapy: Searching for new opportunities grounded in evidence
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease that up to now has been associated with a poor prognosis. However, the results of the INPULSIS and ASCEND trials and the approval of nintedanib and pirfenidone have marked the beginning of a new era for IPF patients. Questio...
Main Authors: | C. Robalo-Cordeiro, P. Campos, L. Carvalho, A. Borba, S. Clemente, S. Freitas, S. Furtado, J.M. Jesus, C. Leal, A. Marques, N. Melo, C. Souto-Moura, S. Neves, V. Sousa, A. Santos, A. Morais |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-09-01
|
Series: | Revista Portuguesa de Pneumologia (English Edition) |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2173511517300787 |
Similar Items
-
Translating Idiopathic pulmonary fibrosis guidelines into clinical practice
by: C. Robalo-Cordeiro, et al.
Published: (2021-01-01) -
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
by: Toby M. Maher, et al.
Published: (2019-09-01) -
Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
by: Keishi Sugino, et al.
Published: (2021-07-01) -
Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
by: S. N. Avdeev, et al.
Published: (2018-10-01) -
Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
by: Jieun Kang, et al.
Published: (2021-09-01)